UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

Comparative Study of the Genetic Barriers and Pathways towards Resistance of Selective Inhibitors of Hepatitis C Virus Replication

Antimicrobial Agents and Chemotherapy, 2011-09, Vol.55 (9), p.4103-4113

2011

Link zum Volltext

Verfügbarkeit prüfen

DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A

PloS one, 2010-10, Vol.5 (10), p.e13687

2010

Link zum Volltext

Verfügbarkeit prüfen

Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors

Antimicrobial Agents and Chemotherapy, 2009-03, Vol.53 (3), p.967-976

2009

Link zum Volltext

Verfügbarkeit prüfen

Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase

Antimicrobial Agents and Chemotherapy, 2011-09, Vol.55 (9), p.4196-4203

2011

Link zum Volltext

Verfügbarkeit prüfen

Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin

Biochemical and biophysical research communications, 2006-09, Vol.348 (1), p.139-144

2006

Link zum Volltext

Verfügbarkeit prüfen

Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors

Antimicrobial Agents and Chemotherapy, 2008-09, Vol.52 (9), p.3433-3437

2008

Link zum Volltext

Verfügbarkeit prüfen

Cytomegalovirus infection aggravates atherogenesis in apoE knockout mice by both local and systemic immune activation

Microbes and infection, 2004, Vol.6 (1), p.17-24

2004

Link zum Volltext

Verfügbarkeit prüfen

Selective inhibitors of picornavirus replication

Medicinal research reviews, 2008-11, Vol.28 (6), p.823-884

2008

Link zum Volltext

Verfügbarkeit prüfen

Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model

Antiviral research, 2018-01, Vol.149, p.150-153

2018

Link zum Volltext

Verfügbarkeit prüfen

Rapid identification of bacteria by real-time amplification and sequencing of the 16S rRNA gene

Journal of microbiological methods, 2006-07, Vol.66 (1), p.156-164

2006

Link zum Volltext

Verfügbarkeit prüfen

Improved detection and quantification of mouse cytomegalovirus by real-time PCR

Virus research, 2003-12, Vol.98 (1), p.17-25

2003

Link zum Volltext

Verfügbarkeit prüfen

In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance

Antiviral research, 2015-08, Vol.120, p.112-121

2015

Link zum Volltext

Verfügbarkeit prüfen

Statins potentiate the in vitro anti‐hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development

Hepatology (Baltimore, Md.), 2009-07, Vol.50 (1), p.6-16

2009

Link zum Volltext

Verfügbarkeit prüfen

Synthesis of new benzimidazole–coumarin conjugates as anti-hepatitis C virus agents

Antiviral research, 2008-02, Vol.77 (2), p.157-162

2008

Link zum Volltext

Verfügbarkeit prüfen

In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors

Journal of hepatology, 2012-01, Vol.56 (1), p.41-48

2012

Link zum Volltext

Verfügbarkeit prüfen

Deletion of the vaccinia virus F13L gene results in a highly attenuated virus that mounts a protective immune response against subsequent vaccinia virus challenge

Antiviral research, 2012-01, Vol.93 (1), p.160-166

2012

Link zum Volltext

Verfügbarkeit prüfen

Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus

European journal of medicinal chemistry, 2013-05, Vol.63, p.290-298

2013

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis C virus-specific directly acting antiviral drugs

Current topics in microbiology and immunology, 2013, Vol.369, p.289

2013

Link zum Volltext

Verfügbarkeit prüfen

Immune activation following cytomegalovirus infection: More important than direct viral effects in cardiovascular disease?

Journal of clinical virology, 2006-03, Vol.35 (3), p.349-353

2006

Link zum Volltext

Verfügbarkeit prüfen

Substituted imidazopyridines as potent inhibitors of HCV replication

Journal of hepatology, 2009-05, Vol.50 (5), p.999-1009

2009

Link zum Volltext

Verfügbarkeit prüfen

Selecting and characterizing drug-resistant hepatitis C virus replicon

Methods in molecular biology (Clifton, N.J.), 2013, Vol.1030, p.93

2013

Link zum Volltext

Verfügbarkeit prüfen

In Vitro Selection and Characterization of Hepatitis C Virus Replicons Double or Triple Resistant to Various Non-nucleoside HCV Polymerase Inhibitors

Antiviral research, 2010-04, Vol.86 (1), p.A19-A20

2010

Link zum Volltext

Verfügbarkeit prüfen

Murine cytomegalovirus infection directs macrophage differentiation into a pro-inflammatory immune phenotype: implications for atherogenesis

Microbes and infection, 2004-10, Vol.6 (12), p.1056-1062

2004

Link zum Volltext

Verfügbarkeit prüfen

Comparative Study of the Genetic Barrier and Pathways Towards Resistance of Selective Inhibitors of HCV Replication

Antiviral research, 2009-05, Vol.82 (2), p.A21-A21

2009

Link zum Volltext

Verfügbarkeit prüfen

In Vitro Combination Therapy with Tegobuvir (GS-9190) is Highly Efficient in Curing Cells from HCV Replicon and in Delaying/Preventing the Development of Antiviral Resistance

Antiviral research, 2011-05, Vol.90 (2), p.A65-A65

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(36)
Buchkapitel
(1)

Sprache

Englisch
(37)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(26)
Humans
(16)
Biological And Medical Sciences
(15)
Antiviral Agents - Pharmacology
(14)
Hepacivirus - Drug Effects
(12)
Infectious Diseases
(12)
Medical Sciences
(12)
Virology
(11)
Pharmacology & Pharmacy
(10)
Animals
(9)
Hepatitis C Virus
(9)
Antiviral Agents
(8)
Cell Line
(8)
Hepacivirus - Genetics
(8)
Microbiology
(8)
Virus Replication - Drug Effects
(8)
Pharmacology. Drug Treatments
(7)
Viral Diseases
(7)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparative Study of the Genetic Barriers and Pathways towards Resistance of Selective Inhibitors of Hepatitis C Virus Replication

DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A

Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors

Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase

Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin

Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors

Cytomegalovirus infection aggravates atherogenesis in apoE knockout mice by both local and systemic immune activation

Selective inhibitors of picornavirus replication

Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model

Rapid identification of bacteria by real-time amplification and sequencing of the 16S rRNA gene

Improved detection and quantification of mouse cytomegalovirus by real-time PCR

In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance

Statins potentiate the in vitro anti‐hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development

Synthesis of new benzimidazole–coumarin conjugates as anti-hepatitis C virus agents

In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors

Deletion of the vaccinia virus F13L gene results in a highly attenuated virus that mounts a protective immune response against subsequent vaccinia virus challenge

Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus

Hepatitis C virus-specific directly acting antiviral drugs

Immune activation following cytomegalovirus infection: More important than direct viral effects in cardiovascular disease?

Substituted imidazopyridines as potent inhibitors of HCV replication

Selecting and characterizing drug-resistant hepatitis C virus replicon

In Vitro Selection and Characterization of Hepatitis C Virus Replicons Double or Triple Resistant to Various Non-nucleoside HCV Polymerase Inhibitors

Murine cytomegalovirus infection directs macrophage differentiation into a pro-inflammatory immune phenotype: implications for atherogenesis

Comparative Study of the Genetic Barrier and Pathways Towards Resistance of Selective Inhibitors of HCV Replication

In Vitro Combination Therapy with Tegobuvir (GS-9190) is Highly Efficient in Curing Cells from HCV Replicon and in Delaying/Preventing the Development of Antiviral Resistance

Suchergebnisse filtern